Premium
FDA warns companies not to promote CBD for opioid addiction
Author(s) -
Knopf Alison
Publication year - 2020
Publication title -
alcoholism and drug abuse weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7591
pISSN - 1042-1394
DOI - 10.1002/adaw.32718
Subject(s) - cannabidiol , food and drug administration , business , opioid , addiction , product (mathematics) , internet privacy , advertising , medicine , psychiatry , risk analysis (engineering) , cannabis , computer science , receptor , geometry , mathematics
The U.S. Food and Drug Administration is warning companies for illegally selling cannabidiol (CBD) by claiming that the product can treat opioid addiction or be used as an alternative to opioids. These claims violate the law, and the warning letters are a continuation of the FDA's efforts to pursue companies that illegally market CBD products with claims that they can treat medical conditions.